secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vaxart, Inc. (VXRT)
CIK:        0000072444
Form:       8-K
Filed at:   2023-08-03T23:59:59+00:00
Accession:  0001437749-23-021953
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Vaxart Q2 2023 net loss improves to $22.6M; norovirus Phase 2 data expected Q3
------------------------------------------------------------------------------

- Net loss of $22.6M ($0.16 per share) vs $29.4M ($0.23) in Q2 2022.
- Revenue of $1.4M from Gates Foundation grant, compared to zero a year ago.
- Cash and marketable securities $67.9M; cash runway extended into Q3 2024.
- Positive preliminary topline data from Phase 2 bivalent norovirus vaccine; all primary endpoints met.
- Topline data from GI.1 norovirus challenge study expected in Q3 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/72444/000143774923021953/0001437749-23-021953-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/72444/000143774923021953/vxrt20230506_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-23-021953

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer